10 recruiting, 3 completed, 2 not yet recruiting. 9 Phase 3, 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Recruiting 8, Not yet recruiting 1 |
| Phase 1 | 3 | Completed 1, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 3 | Completed 2, Recruiting 1 |
Follow REGN7508: new trials by email Literature Review of REGN7508 trials Research Report on REGN7508
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Healthy Adult Participants Trial Comparing Different Cenvacibart Presentations Cenvacibart - Healthy Volunteers | Phase 1 | Not yet recruiting | Regeneron Pharmaceuticals | 80 | 2026-11-23 | 2026-10-15 |
| A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants Cenvacibart, Placebo - Secondary Stroke | Phase 3 | Not yet recruiting | Regeneron Pharmaceuticals | 6106 | 2026-11-20 | 2026-10-15 |
| Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis REGN9933, REGN7508, REGN9533 - End-Stage Kidney Disease (ESKD) | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 36 | 2026-09-17 | 2026-10-06 |
| Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC) REGN7508, REGN9933, Placebo - Venous Thromboembolism (VTE) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 1908 | 2026-09-07 | 2026-09-29 |
| Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers REGN7508, Apixaban - Venous Thromboembolism (VTE) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 1600 | 2026-08-26 | 2026-10-21 |
| Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation REGN7508, Apixaban, Placebo - Atrial Fibrillation (AF) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 15364 | 2026-08-10 | 2026-10-26 |
| Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease REGN7508, REGN9933, Placebo - Peripheral Artery Disease (PAD) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 7050 | 2026-07-10 | 2026-10-22 |
| Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable REGN7508, REGN9933, Placebo - Atrial Fibrillation (AF) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 2628 | 2026-04-03 | 2026-10-14 |
| REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis REGN7508, Placebo - Cancer-Associated Thrombosis (CAT) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 1120 | 2026-03-09 | 2026-10-13 |
| REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants REGN7508, Acetylsalicylic Acid (ASA), Placebo - Symptomatic Venous Thromboembolism (VTE) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 2000 | 2025-11-24 | 2026-10-22 |
| Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation REGN7508, REGN9933, Apixaban - Atrial Fibrillation (AF) | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 1200 | 2025-10-20 | 2026-10-21 |
| REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults REGN7508, Apixaban, Enoxaparin - Venous Thromboembolism (VTE) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 2000 | 2025-06-25 | 2026-10-08 |
| Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants Aspirin, REGN9933, REGN7508 - Healthy Volunteers | Phase 1 | Completed | Regeneron Pharmaceuticals | 224 | 2024-09-30 | 2025-07-16 |
| A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC) REGN9933, REGN7508, Placebo - Venous Thromboembolism | Phase 2 | Completed | Regeneron Pharmaceuticals | 195 | 2024-09-20 | 2026-04-13 |
| A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants REGN7508, Enoxaparin - Venous Thromboembolism | Phase 2 | Completed | Regeneron Pharmaceuticals | 179 | 2024-06-27 | 2026-05-27 |
Venous Thromboembolism (7) · Thrombosis (6) · Hemorrhage (5) · Pulmonary Embolism (4) · Atrial Fibrillation (3) · Stroke (3) · Venous Thrombosis (3) · Ischemic Stroke (2) · Neoplasms (2) · Kidney Failure, Chronic (1) · Peripheral Arterial Disease (1) · Renal Insufficiency, Chronic (1)
Regeneron Pharmaceuticals (15)
United States (9) · Bulgaria (4) · Canada (4) · Japan (4) · Romania (3) · United Kingdom (3) · Georgia (2) · Hungary (2) · Latvia (2) · Lithuania (2) · Poland (2) · Argentina (1) · Belgium (1) · Brazil (1) · Greece (1)
2025 (5), 2023 (2)